A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

← catalyst calendar

NCT07029828 · readout in 1,407 d

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase

Phase 3

Status

Recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

140estimated

Sites

Countries

China, Czechia, France +3

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-09-10

actual

When the study began enrolling

Primary completion

2030-06-26

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2030-06-26

estimated

The whole study's end, after follow-up

First posted

2025-06-19

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-04-28

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Severe Alopecia Areata

Interventions

Drug: Ritlecitinib higher dose
Drug: Ritlecitinib lower dose

Primary outcomes

what the primary-completion date above is the date OF

Incidence of treatment-emergent adverse events (AEs).

measured From the time participant signs informed consent/assent, through and including a minimum of 28 calendar days after the last administration of the study intervention (up to approximately 3 years).

Incidence of Serious Adverse Events (SAEs) and AEs leading to permanent discontinuation from the study.

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed